institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published 12 days ago • loading... • Updated 12 days ago

Amgen Eyes 2026 ‘Springboard’ as Growth Drugs Offset Patent Pressure

Summary by marketbeat.com

Amgen (NASDAQ:AMGN) executives said the company’s first-quarter performance supports its view that 2026 can serve as a “springboard year,” with growth products helping offset increased competition for the denosumab franchise and other losses of exclusivity. Speaking at a Goldman Sachs event, Peter

1 Articles

1 Articles

Amgen Eyes 2026 ‘Springboard’ as Growth Drugs Offset Patent Pressure

Amgen (NASDAQ:AMGN) executives said the company’s first-quarter performance supports its view that 2026 can serve as a “springboard year,” with growth products helping offset increased competition for the denosumab franchise and other losses of exclusivity. Speaking at a Goldman Sachs event, Peter

12 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Father's Day SaleGet 40% off Vantage subscriptions for yourself or a friend.Get Started

Coverage Details

Total News Sources1

Leaning Left0Leaning Right0Center1Last Updated12 days agoBias Distribution

100% Center

Bias Distribution

100% of the sources are Center

100% Center

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

marketbeat.com broke the news 12 days ago on Tuesday, June 9, 2026.

Sources are mostly out of (0)

Similar News Topics

Stories disproportionately reported by the Left or the Right

Similar News Topics